What is HC Wainwright’s Forecast for ACHV FY2030 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for Achieve Life Sciences in a research note issued to investors on Monday, January 26th. HC Wainwright analyst B. Folkes forecasts that the biopharmaceutical company will post earnings of $1.64 per share for the year. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04).

Several other brokerages have also issued reports on ACHV. Citigroup began coverage on Achieve Life Sciences in a research report on Tuesday, November 25th. They issued an “outperform” rating for the company. Citizens Jmp started coverage on Achieve Life Sciences in a report on Tuesday, November 25th. They issued a “market outperform” rating and a $19.00 price objective for the company. Raymond James Financial restated a “strong-buy” rating on shares of Achieve Life Sciences in a report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Achieve Life Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Achieve Life Sciences Price Performance

ACHV stock opened at $5.09 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.14 and a quick ratio of 5.14. Achieve Life Sciences has a 1 year low of $1.84 and a 1 year high of $6.03. The firm has a 50-day moving average of $4.84 and a 200 day moving average of $3.87. The company has a market cap of $270.94 million, a P/E ratio of -3.69 and a beta of 1.71.

Institutional Investors Weigh In On Achieve Life Sciences

A number of institutional investors have recently modified their holdings of ACHV. ADAR1 Capital Management LLC increased its position in shares of Achieve Life Sciences by 10.7% during the 3rd quarter. ADAR1 Capital Management LLC now owns 47,800 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 4,627 shares during the period. Bank of America Corp DE boosted its position in shares of Achieve Life Sciences by 39.9% in the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 9,617 shares during the period. AQR Capital Management LLC purchased a new position in shares of Achieve Life Sciences in the first quarter worth approximately $32,000. Next Capital Management LLC purchased a new position in Achieve Life Sciences during the 3rd quarter worth approximately $51,000. Finally, OneDigital Investment Advisors LLC purchased a new position in shares of Achieve Life Sciences during the third quarter valued at $63,000. 33.52% of the stock is owned by hedge funds and other institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.